Properties (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
ophthalmic solution
|
| gptkbp:activeDuring |
netarsudil
latanoprost |
| gptkbp:administrativeDivision |
shake well before use
do not touch dropper tip apply pressure to the inner corner of the eye after administration |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableSizes |
one drop once daily
|
| gptkbp:clinicalTrials |
Phase 3
well tolerated chronic open-angle glaucoma effective in lowering IOP ocular hypertension |
| gptkbp:contains |
netarsudil
latanoprost |
| gptkbp:contraindication |
eye discomfort
hypersensitivity to components foreign body sensation conjunctival hyperemia |
| gptkbp:dosageForm |
topical solution
|
| gptkbp:drugInterdiction |
true
Rho kinase inhibitor prostaglandin analog |
| gptkbp:expirationDate |
24 months
|
| gptkbp:hasCompetitors |
other glaucoma medications
generic alternatives available |
| gptkbp:hasPopulation |
adults
elderly |
| https://www.w3.org/2000/01/rdf-schema#label |
Roclatan
|
| gptkbp:impact |
as prescribed by physician
|
| gptkbp:issuedBy |
eye drops
|
| gptkbp:lastProduced |
2017
|
| gptkbp:mandates |
intraocular pressure reduction
|
| gptkbp:manufacturer |
gptkb:Aerie_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:United_States Europe |
| gptkbp:packaging |
bottle
|
| gptkbp:patentExpiration |
2027
|
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryCompliance |
monitored for safety
approved for marketing |
| gptkbp:researchFocus |
combination therapies
long-term efficacy safety in special populations |
| gptkbp:route |
ocular
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
headache
blurred vision eye irritation hyperemia |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
increases aqueous humor outflow
reduces intraocular pressure |
| gptkbp:usedFor |
glaucoma
|